Inhibikase Therapeutics Announces Inducement Grants

Biotech firm grants stock options to new hires under Nasdaq rule

Apr. 3, 2026 at 6:19pm

Got story updates? Submit your updates here. ›

A minimalist studio still life photograph featuring a stack of pharmaceutical pill bottles, a syringe, and a medical stethoscope arranged elegantly on a clean, white background, conceptually representing the clinical development of new drugs.Inhibikase Therapeutics' new inducement grants underscore its dedication to building a talented team to advance its pipeline of cardiopulmonary disease treatments.Wilmington Today

Inhibikase Therapeutics, a clinical-stage pharmaceutical company, announced that it has granted non-qualified stock options to purchase up to an aggregate of 685,718 shares of the company's common stock to five newly-hired non-executive employees. The inducement grants were approved by the Compensation Committee of the company's Board of Directors as a material inducement to the new employees' entry into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters

The inducement grants are a common practice for publicly-traded companies to attract and retain top talent, especially in the competitive biotech industry. These grants provide the new employees with a financial incentive to contribute to the company's success and align their interests with those of shareholders.

The details

The options have an exercise price of $1.68 per share, which is equal to the closing price of the company's common stock on the effective date of March 31, 2026. The options have a ten-year term, with 25% vesting on the first anniversary of the effective date and the remaining 75% vesting in 36 equal monthly installments thereafter.

  • The inducement grants were effective as of March 31, 2026.
  • The options have a ten-year term.

The players

Inhibikase Therapeutics, Inc.

A clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, including Pulmonary Arterial Hypertension (PAH).

Got photos? Submit your photos here. ›

The takeaway

The inducement grants demonstrate Inhibikase Therapeutics' commitment to building a strong team of talent to advance its clinical pipeline and drive growth. These types of equity-based incentives are a common practice in the biotech industry to attract and retain top talent.